News

The Charcot-Marie-Tooth Association (CMTA) congratulates CMTA-STAR Alliance Partner NMD Pharma A/S (NMD Pharma) on initiating its Phase II SYNAPSE-CMT trial. This significant milestone reflects a shared commitment to advancing therapeutic options for individuals living with CMT. The trial’s first patient ...

The Charcot-Marie-Tooth Association (CMTA), through its strategic alliance with the Inherited Neuropathy Consortium (INC), is proud to announce the 2025 Inherited Neuropathy Fellowship. This one-year fellowship highlights how the CMTA-INC alliance drives progress by equipping the next generation of clinicians ...

CMTA strengthens its role as the leading force in comprehensive CMT research, forging a strategic alliance with the Inherited Neuropathy Consortium The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth disease (CMT) research aimed at bringing treatments to patients, today ...

Exciting news from a CMTA-STAR-funded research project has been published by Jordan VerPlank, PhD, Assistant Professor in the Department of Anatomy, Physiology, and Genetics at the Uniformed Services University of the Health Sciences (USU). The paper, published in Cellular and ...

In a jointly-funded project between CMTA and the Muscular Dystrophy Association (MDA), Alexia Kagiava, PhD, and her team at the Cyprus Institute of Neurology and Genetics in Cyprus are pioneering the use of nanoparticles to deliver gene therapies directly ...